|
|||||
|
|
Analysis of Real‐World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD |
|
| Authors: | Saad Usmani Tahamtan Ahmadi Yvette Ng Annette Lam Avinash Desai Ravi Potluri Maneesha Mehra |
| Affiliation: | 1. Levine Cancer Institute/Carolinas Health Care System, Charlotte, North Carolina, USA;2. Janssen Research and Development, LLC, Spring House, Pennsylvania, USA;3. Janssen Global Services, LLC, Raritan, New Jersey, USA;4. SmartAnalyst, Inc., New York, New York, USA |
| Abstract: | |
| Keywords: | Multiple myeloma Survival analysis Electronic health records Retrospective studies |